Introduction
============

Osteosarcoma is the most common primary malignant bone tumor among children and adults worldwide and is characterized by a high metastatic potential to the lung as well as poor prognosis ([@b1-mmr-18-01-0779],[@b2-mmr-18-01-0779]). Long non-coding (lnc)RNAs are sequences of non-coding protein transcripts (\>200 nucleotides in length) with little or no protein-coding capacity ([@b3-mmr-18-01-0779]). Unlike mRNAs, lncRNAs are associated with numerous biological and cellular processes, including the regulation of transcription and mRNA post-transcriptional levels ([@b4-mmr-18-01-0779],[@b5-mmr-18-01-0779]). Previous studies have revealed that lncRNAs are responsible for initiation and progression of numerous cancers due to their involvement in cellular processes ([@b6-mmr-18-01-0779]--[@b8-mmr-18-01-0779]). Notably, a number of functional lncRNAs have previously been revealed to be associated with osteosarcoma, including HOX transcript antisense RNA (AS) ([@b9-mmr-18-01-0779]), breast cancer anti-estrogen resistance 4 ([@b10-mmr-18-01-0779]), HOXA distal transcript AS ([@b11-mmr-18-01-0779]) and urothelial cancer associated 1 ([@b12-mmr-18-01-0779]). Numerous lncRNAs function as the antisense partners of their respective protein-coding genes, including cyclin dependent kinase inhibitor 2B-AS1 ([@b13-mmr-18-01-0779],[@b14-mmr-18-01-0779]), C-terminal binding protein 1-AS ([@b15-mmr-18-01-0779]), hepatocyte nuclear factor 1 homeobox A-AS1 ([@b16-mmr-18-01-0779]) and proliferation arrest specific 6-AS1 ([@b17-mmr-18-01-0779]).

LncRNA WW domain-containing oxidoreductase (WWOX)-AS1 is an antisense transcript of *WWOX* ([@b18-mmr-18-01-0779]). Furthermore, *WWOX* has been demonstrated to be strongly associated with numerous cancer types, including ovarian cancer ([@b19-mmr-18-01-0779]), hepatocellular carcinoma ([@b20-mmr-18-01-0779]), colon cancer ([@b21-mmr-18-01-0779]) and bladder cancer ([@b22-mmr-18-01-0779]). In addition, the expression levels and functions of antisense lncRNAs are frequently associated with their corresponding protein-coding genes ([@b13-mmr-18-01-0779]--[@b17-mmr-18-01-0779]). It has previously been demonstrated that lncRNA WWOX-AS1 is associated with ovarian cancer and that its overexpression inhibits the proliferation, migration and invasion of epithelial ovarian cancer cells ([@b18-mmr-18-01-0779]). Furthermore, previous studies have also revealed that *WWOX* expression is associated with osteosarcoma and that its overexpression inhibits the progression of osteosarcoma ([@b23-mmr-18-01-0779],[@b24-mmr-18-01-0779]). Therefore, it may be suggested that the expression and function of WWOX-AS1 are associated with the progression and prognosis of osteosarcoma.

In the present study, a number of experiments were performed to investigate the functional role of WWOX-AS1 in osteosarcoma. The expression of WWOX-AS1 in osteosarcoma tissues, its association with patient prognosis and its correlation with *WWOX* expression levels were investigated. Furthermore, functional assays were performed via the knockdown and overexpression experiments. In conclusion, the results of the present study demonstrated the functional role of WWOX-AS1 in osteosarcoma, which may prove valuable for future osteosarcoma research.

Materials and methods
=====================

### Study participants

A total of 70 patients with osteosarcoma were recruited in the present study ([Table I](#tI-mmr-18-01-0779){ref-type="table"}). The 70 patients with osteosarcoma were classified into two groups: High-WWOX-AS1 group (n=35; WWOX-AS1 expression value ≥median value) and low-WWOX-AS1 group (n=35; WWOX-AS1 expression value ≤median value). Staging is based on Enneking system staging ([@b25-mmr-18-01-0779]). From each patient, an osteosarcoma tissue sample and an adjacent tissue sample were collected via appropriate surgical resections. The samples were collected between March 2011 and December 2014 in the General Hospital of the People\'s Liberation Army (Beijing, China). Written informed consent was obtained from each patient or their guardians. The present study was approved by the Ethics Committees of the General Hospital of the People\'s Liberation Army.

### Cancer cell lines

Three human osteosarcoma cell lines (SAOS2, MG63 and U2OS) and a normal human osteoblastic cell line (hFOB) were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco\'s Modified Eagle\'s Medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin/streptomycin solution (Invitrogen, Thermo Fisher Scientific, Inc.) at 37°C and 5% CO~2.~

### RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from patients\' tissues and cell lines using TRIzol Total RNA Reagent (Life Technologies; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Complementary (c)DNA was synthesized from 2 µg total RNA using the RevertAid™ H Minus First Strand cDNA Synthesis kit (Takara Bio, Inc., Otsu, Japan) and cDNA was stored at −20°C. The RT reactions were terminated by inactivation at 95°C for 10 min and stored at 4°C. Primers used were obtained from Chang Jing Bio-Tech, Ltd. (Changsha, China) and were identical to those used in our previously published study ([@b18-mmr-18-01-0779]); they are presented in [Table II](#tII-mmr-18-01-0779){ref-type="table"}. qPCR was performed using the SYBR PrimeScript RT-PCR kit (Takara Bio, Inc.) in an Applied Biosystems 7500 Fluorescent Quantitative PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions used were as follows: 95°C for 30 sec; followed by 40 amplification cycles at 95°C for 5 sec and 60°C for 34 sec. The values were normalized to the internal control products of β-actin. Quantification of gene expression was performed using the 2^−ΔΔCq^ method ([@b26-mmr-18-01-0779]), with Cq representing the threshold cycle. Target gene expression per sample was determined using the following equation: Target in tumor tissue/target in non-tumorous tissue. All reactions were performed in triplicate and normalized to β-actin expression.

### Knockdown of WWOX-AS1 in SAOS2 cells

Small interfering (si)RNA sequences specific to WWOX-AS1 and negative control (NC) siRNA were obtained from Chang Jing Bio-Tech, Ltd and termed WWOX-AS1-si-1 and WWOX-AS1-si-2 (NC) separately. The siRNA sequences used are also presented in [Table III](#tIII-mmr-18-01-0779){ref-type="table"}, and were identical to those used in our previously published study ([@b18-mmr-18-01-0779]). A total of 2×10^3^ SAOS2 cells were plated in 6-well plates and then separately transfected with 50 nmol/l WWOX-AS1-si-1 and 50 nmol/l WWOX-AS1-si-2 (NC) *in vitro* using Lipofectamine^®^ RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. The cells in the wells were exposed to the transfection mixture for 24 h at 37°C prior to the subsequent experiments.

### Overexpression of WWOX-AS1 in osteosarcoma cells

WWOX-AS1 was cloned into BamHI-EcoRI sites of plasmid complementary (pc)DNA3.1 vectors (Promega Corporation, Madison, WI, USA). The MG63 cells that expressed low levels of WWOX-AS1 were transfected with 100 ng pcDNA-WWOX-AS1 or empty vector using Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The cells in the wells were exposed to the transfection mixture for 24 h at 37°C prior to the subsequent experiments.

### Cell proliferation assay

Cell proliferation was investigated using a MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay kit (Promega Corporation, Madison, WI, USA) in accordance with the manufacturer\'s protocol. MG63 and SAOS2 cells (2,000 cells/well) were separately plated in 96-well plates. MTS reagent (20 µl) was added to each well containing 100 µl DMEM culture medium supplemented with 10% FBS. Plates were subsequently incubated for 2 h at 37°C in a humidified atmosphere containing 5% CO~2~. The absorbance was measured at a wavelength of 490 nm using a plate reader. The optical density (OD) values at 24, 48, 72 and 96 h following transfection were determined and normalized to the OD value at 0 h. Relative cell proliferation was subsequently determined.

### Scratch wound-healing assay

A total of 24 h post-transfection, MG63 and SAOS2 cells were seeded into a 6-well culture plate until a confluent monolayer was established and then cultured at 37°C. Following this, uniform wounds were scraped using a sterile 200 µl pipette tip and each well was washed thrice using 1X PBS to remove floating cells. The initial gap length (0 h) and the residual gap length (48 h) following wound initiation were calculated from images acquired using a fluorescence inversion microscope system (Nikon Corporation, Tokyo, Japan) at a magnification of ×200.

### Matrigel invasion assay

Cell invasion assays were performed using modified Boyden Chambers (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer\'s protocol. A total of 2×10^3^ cells were suspended in 100 µl of DMEM supplemented with 10% FBS in the lower chamber, and then plated in upper chambers with Matrigel-coated inserts (pore size, 8 µm) in 24-well culture plates (BD Biosciences). Invasive cells were stained at 42°C using 0.1% crystal violet solution for 15 min and counted whilst passing through the filter. The average invasion rate was calculated using a fluorescence inversion microscope system (Nikon Corporation) at a magnification of ×200; the increasing number of invasive cells as a proportion of the entire cell population after 48 h.

### Statistical analysis

Each experiment was repeated at least three times. The Student\'s t-test and one-way analysis of variance followed by the Newman-Keuls method were performed to analyze the statistical differences between two groups and multiple groups, respectively. The χ^2^ test was used to perform correlation analysis of clinical data. Correlation between gene expression levels was investigated using Pearson\'s correlation coefficient. Survival analysis was performed using the Kaplan-Meier method, and differences between the survival probabilities of each patient group were compared using a log-rank test. The values are expressed as the mean ± standard deviation. Data analyses were performed using SPSS software (version 18.0; SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### WWOX-AS1 is downregulated in osteosarcoma and is associated with prognosis of patients

WWOX-AS1 expression in osteosarcoma tissues was significantly downregulated in tumor tissues compared with adjacent normal tissues ([Fig. 1A](#f1-mmr-18-01-0779){ref-type="fig"}). Furthermore, WWOX-AS1 expression was revealed to be lowest in patients with World Health Organization (WHO) grade III osteosarcoma, and highest in patients with WHO grade I osteosarcoma ([Fig. 1B](#f1-mmr-18-01-0779){ref-type="fig"}). In osteosarcoma tissue specimens, the association between WWOX-AS1 expression and the prognosis of patients with osteosarcoma was investigated using the Kaplan-Meier and log-rank tests. The 70 patients with osteosarcoma were classified into two groups: High-WWOX-AS1 group (n=35; WWOX-AS1 expression value ≥median value) and low-WWOX-AS1 group (n=35; WWOX-AS1 expression value ≤median value). The results suggested that the overall survival probability of the high-WWOX-AS1 group was significantly increased compared with the low-WWOX-AS1 group ([Fig. 1C](#f1-mmr-18-01-0779){ref-type="fig"}; P=0.036), which suggested that downregulation of WWOX-AS1 may serve an important role in the progression of osteosarcoma. As revealed in [Table IV](#tIV-mmr-18-01-0779){ref-type="table"}, significant differences were observed between WWOX-AS1 expression and pulmonary metastasis as well as WHO grade in the two different patient groups (P\<0.05). However, no significant associations were revealed between WWOX-AS1 expression and sex, age, tumor size or differentiation ([Table IV](#tIV-mmr-18-01-0779){ref-type="table"}).

### Expression of WWOX-AS1 is positively correlated with WWOX expression

The association between WWOX-AS1 and *WWOX* was investigated using RT-qPCR. The results suggested that WWOX-AS1 and *WWOX* expression were positively correlated (R=0.46, P\<0.001; [Fig. 2](#f2-mmr-18-01-0779){ref-type="fig"}).

### Alterations in WWOX expression correspond with the expression of WWOX-AS1 following WWOX-AS1 overexpression or knockdown in osteosarcoma cell lines

The expression of WWOX-AS1 was investigated in three human osteosarcoma cell lines (SAOS2, MG63 and U2OS) and one human normal osteoblastic cell line (hFOB) using RT-qPCR. The results demonstrated that the expression level of WWOX-AS1 in hFOB was significantly increased compared with all three human osteosarcoma cell lines. Furthermore, SAOS2 and U2OS cells were revealed to exhibit a significantly enhanced expression of WWOX-AS1 compared with MGC3 cells ([Fig. 3A](#f3-mmr-18-01-0779){ref-type="fig"}).

In addition, WWOX-AS1 overexpression was analyzed using RT-qPCR. WWOX-AS1 pcDNA was constructed and transfected into MG63 cells. The results verified that WWOX-AS1 expression was significantly enhanced in the pcDNA WWOX-AS1 group compared with the pcDNA control group. In addition, the result revealed that WWOX expression was also significantly upregulated in the pcDNA WWOX-AS1 group compared with the pcDNA control group ([Fig. 3B](#f3-mmr-18-01-0779){ref-type="fig"}).

Furthermore, WWOX-AS1 knockdown was investigated via RT-qPCR. WWOX-AS1 siRNA was transfected into SAOS2 cells, and the results demonstrated that both WWOX-AS1 and *WWOX* expression levels were significantly downregulated in the WWOX-AS1 siRNA group compared with the NC group ([Fig. 3C](#f3-mmr-18-01-0779){ref-type="fig"}). Therefore, the results suggested that *WWOX* expression may be regulated by lncRNA WWOX-AS1 in osteosarcoma.

### Proliferation, migration and invasion abilities of MG63 cells are suppressed following WWOX-AS1 overexpression

To investigate the role of WWOX-AS1 in osteosarcoma, WWOX-AS1 overexpression in MG63 cells was performed. The results demonstrated that the proliferation of MG63 cells transfected with pcDNA WWOX-AS1 was significantly inhibited compared with the pcDNA control group with increased time ([Fig. 4A](#f4-mmr-18-01-0779){ref-type="fig"}). In addition, the results of the wound healing assay revealed that the migration of MG63 cells transfected with pcDNA WWOX-AS1 was significantly suppressed compared with the pcDNA control group ([Fig. 4B](#f4-mmr-18-01-0779){ref-type="fig"}). Furthermore, the results of the Matrigel invasion assay demonstrated that the invasive ability of cells transfected with pcDNA WWOX-AS1 was significantly decreased compared with the pcDNA control group ([Fig. 4C](#f4-mmr-18-01-0779){ref-type="fig"}). In conclusion, the results suggested that the proliferation, migration and invasion of MG63 cells were suppressed following WWOX-AS1 overexpression.

### Proliferation, migration and invasion of SAOS2 cells are enhanced following WWOX-AS1 knockdown

To further investigate the role of WWOX-AS1 in osteosarcoma, WWOX-AS1 knockdown in SAOS2 cells was performed. The results demonstrated that proliferation of cells transfected with WWOX-AS1 siRNA was significantly enhanced compared with the NC group with increased time ([Fig. 5A](#f5-mmr-18-01-0779){ref-type="fig"}). The results of the scratch wound-healing assay revealed that cell migration in the WWOX-AS1 siRNA group was significantly enhanced compared with the NC group ([Fig. 5B](#f5-mmr-18-01-0779){ref-type="fig"}). In addition, the results of the Matrigel invasion assay demonstrated that cell invasion was significantly increased in the WWOX-AS1 siRNA group compared with the NC group ([Fig. 5C](#f5-mmr-18-01-0779){ref-type="fig"}). In conclusion, the results suggested that the proliferation, migration and invasion of SAOS2 cells were enhanced following WWOX-AS1 knockdown.

Discussion
==========

Osteosarcoma is the most prevalent primary bone tumor in children, adolescents and elderly adults ([@b1-mmr-18-01-0779]). In recent years, a number of therapeutic strategies have been used in the treatment of osteosarcoma, including surgery, multiagent chemotherapy and traditional Chinese medical treatments ([@b27-mmr-18-01-0779]--[@b33-mmr-18-01-0779]). However, current treatments for osteosarcoma are still limited in their effectiveness, as the molecular mechanisms underlying the pathogenesis of osteosarcoma have not been fully determined. Therefore, to improve outcomes for patients, it is important to elucidate the potential mechanism and underlying regulation process in osteosarcoma.

Previously, it has been demonstrated that antisense lncRNAs may regulate their sense transcript in a positive or negative manner ([@b34-mmr-18-01-0779]--[@b36-mmr-18-01-0779]). Furthermore, numerous antisense lncRNAs have been revealed to be associated with numerous malignant tumors ([@b13-mmr-18-01-0779]--[@b17-mmr-18-01-0779]). LncRNA WWOX-AS1 is the antisense transcript of *WWOX* and has been demonstrated to regulate the progression of numerous cancers, including osteosarcoma ([@b23-mmr-18-01-0779],[@b24-mmr-18-01-0779]), ovarian cancer ([@b19-mmr-18-01-0779]), hepatocellular carcinoma ([@b20-mmr-18-01-0779]), colon cancer ([@b21-mmr-18-01-0779]) and bladder cancer ([@b22-mmr-18-01-0779]). However, the effect of WWOX-AS1 on the progression of osteosarcoma remains undetermined. The present study investigated the expression level of WWOX-AS1 in human tissues and osteosarcoma cell lines. The functional role of WWOX-AS1 was also analyzed in osteoblastic cell lines. The results revealed that the expression of WWOX-AS1 was downregulated in osteosarcoma tissues and cell lines compared with healthy tissues and normal human osteoblastic cells, respectively. The association between prognosis of patients and WWOX-AS1 expression was also determined using Kaplan-Meier and log-rank tests, which suggested that patients with high WWOX-AS1 expression exhibited a greater overall survival compared with patients with low WWOX-AS1 expression. Furthermore, the results of the present study demonstrated that WWOX-AS1 and *WWOX* expression levels were positively correlated in patients. In addition, the expression levels of *WWOX* were revealed to be significantly enhanced and suppressed following WWOX-AS1 overexpression and knockdown in osteosarcoma cell lines, respectively; which further suggested that the expression levels of WWOX-AS1 and *WWOX* are positively correlated in osteosarcoma. These results suggested that lncRNA WWOX-AS1 may regulate *WWOX* expression. Similar results were also demonstrated in our previous study regarding ovarian cancer ([@b18-mmr-18-01-0779]).

To date, numerous lncRNAs have been identified as potent prognostic predictors in the progression of osteosarcoma ([@b9-mmr-18-01-0779]--[@b12-mmr-18-01-0779]). Therefore, the present study aimed to determine whether lncRNA WWOX-AS1 could suppress tumor progression as well as suppress the proliferation, migration and invasion of cells associated with osteosarcoma. The results demonstrated that decreased expression of WWOX-AS1 was correlated with elevated WHO grades, and that patients in the high-WWOX-AS1 group demonstrated a greater overall survival compared with patients in the low-WWOX-AS1 group. Therefore, it can be suggested that WWOX-AS1 is associated with tumor development in osteosarcoma. This may be attributed to the association between WWOX and the prognosis of osteosarcoma. For example, Zhang *et al* ([@b23-mmr-18-01-0779]) demonstrated that *WWOX* gene polymorphisms may represent predictive factors for the assessment of risks and outcomes associated with osteosarcoma. Kurek *et al* ([@b37-mmr-18-01-0779]) revealed the occurrence and frequency of *WWOX* deletion in osteosarcoma as well as the prognostic and therapeutic significance of *WWOX* in osteosarcoma. The results of the present study demonstrated that WWOX-AS1 overexpression suppressed the proliferation, migration and invasion of MG63 cells. In addition, the results demonstrated that WWOX-AS1 knockdown enhanced the proliferation, migration and invasion of SAOS2 cells. These results demonstrated the inhibitory role of WWOX-AS1 on the proliferation, migration and invasion abilities of osteosarcoma cells. Previous studies have demonstrated that, as a tumor suppressor gene, *WWOX* could suppress the proliferation, migration, invasion and tumorigenicity of osteosarcoma cells ([@b38-mmr-18-01-0779]), most likely via regulation of runt related transcription factor 2 (RUNX2) ([@b24-mmr-18-01-0779]). This further suggests that there is an association between WWOX-AS1 and *WWOX*. In addition, genes regulated by *WWOX* in osteosarcoma may provide important information regarding the underlying mechanism of WWOX-AS1 in osteosarcoma. RUNX2 has been previously demonstrated to activate genes associated with angiogenesis (vascular endothelial growth factor and osteopontin) ([@b39-mmr-18-01-0779]), metastasis and invasion \[matrix metallopeptidase (MMP)2, MMP9 and MMP13\] ([@b40-mmr-18-01-0779],[@b41-mmr-18-01-0779]), and survival (survivin) ([@b42-mmr-18-01-0779]). It has been previously demonstrated that *WWOX* loss of function is associated with osteosarcoma progression by inhibition of numerous genes involved in metastasis via regulation of RUNX2 ([@b24-mmr-18-01-0779]). Furthermore, a previous study demonstrated that investigation into the genomic function of RUNX2 in osteosarcoma cells provides insight into dysregulated molecular pathways in bone cancer ([@b43-mmr-18-01-0779]). Therefore, it may be hypothesized that the molecular mechanisms underlying the involvement of WWOX-AS1 in osteosarcoma may be associated with RUNX2 or genes activated by RUNX2.

The present study, to the best of the authors knowledge, is the first to investigate the functional role of WWOX-AS1 in osteosarcoma. The results of the present study may provide novel insight into the roles of WWOX-AS1 in osteosarcoma, and whether WWOX-AS1 may represent a promising therapeutic target and novel biomarker for the treatment of osteosarcoma.

However, there were certain limitations to the present study. First, clinical information and samples were only collected from Chinese patients with osteosarcoma, therefore limiting the generalizability of the results. Second, *in vivo* experiments were performed using si-WWOX-AS1; however, it failed to achieve stable results (data not shown in this study). The silencing effect induced by exogenous delivery of synthetic siRNAs is transient and reactivation of the target gene typically occurs with a few days\' interval ([@b44-mmr-18-01-0779]). siRNA as exogenous RNA is easily degraded by nuclease *in vivo* and can therefore lead to unstable results. In addition, the present study did not investigate the association between WWOX-AS1 expression and apoptosis. Furthermore, the exact molecular mechanism of WWOX-AS1 was not determined in the present study. Considering these limitations, more extensive collection of comprehensive clinical information and subsequent analyses are required to further verify the results of the present study. Our future studies will aim to investigate the mechanisms underlying the association between WWOX-AS1 and osteosarcoma using viral transfection, and to establish stable cell lines. Future studies should further investigate important genes (including RUNX2) and signaling pathways associated with WWOX-AS1 in osteosarcoma.
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###### 

Relative expression of WWOX-AS1 in tissue samples obtained from 70 patients with osteosarcoma investigated using reverse transcription-polymerase chain reaction and normalized to β-actin expression. (A) WWOX-AS1 expression was significantly decreased in tumor tissues compared with normal tissues. \*P\<0.05 vs. the normal group. (B) WWOX-AS1 expression was decreased in patients with WHO grade III osteosarcoma and greatest in patients with WHO grade I osteosarcoma. \*P\<0.05. (C) Kaplan-Meier overall survival curves on the basis of WWOX-AS1 expression level. Patients with high WWOX-AS1 expression (n=35; WWOX-AS1 expression ratio ≥median ratio) demonstrated a greater overall survival compared with patients with low WWOX-AS1 expression (n=35; WWOX-AS1 expression ratio ≤median ratio; P=0.036). WWOX, WW domain-containing oxidoreductase; WWOX-AS1, WWOX antisense RNA 1; WHO, World Health Organization; T/N, target in tumor tissue/target in non-tumorous tissue.
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![Correlation analysis demonstrates a positive correlation between WWOX-AS1 and WWOX expression in osteosarcoma tissue samples. WWOX, WW domain-containing oxidoreductase; WWOX-AS1, WWOX antisense RNA 1.](MMR-18-01-0779-g03){#f2-mmr-18-01-0779}

###### 

WWOX and WWOX-AS1 expression levels are increased in MG63 cells transfected with pcDNA WWOX-AS1 and decreased in SAOS2 cells transfected with WWOX-AS1-si. (A) Among the three human osteosarcoma cell lines investigated, the expression of WWOX-AS1 was revealed to be greatest in SAOS2 cells and lowest in MG63 cells. (B) WWOX-AS1 and WWOX expression levels were significantly upregulated in MG63 cells following transfection with pcDNA-WWOX-AS1. (C) WWOX-AS1 and WWOX expression levels were significantly decreased in SAOS2 cells following transfection with WWOX-AS1-si. \*P\<0.05 and \*\*P\<0.01. WWOX, WW domain-containing oxidoreductase; WWOX-AS1, WWOX antisense RNA 1; NC, negative control; si, small interfering RNA; pcDNA, plasmid complementary DNA.
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###### 

Proliferation, migration and invasion of MG63 cells are suppressed following transfection with pcDNA WWOX-AS1 (magnification, ×200). (A) Proliferation of MG63 cells transfected pcDNA WWOX-AS1 was significantly decreased compared with the pcDNA control group. (B) Scratch wound healing assays revealed that migration of MG63 cells transfected with pcDNA WWOX-AS1 was significantly suppressed compared with the pcDNA control group. (C) Matrigel invasion assays revealed that the invasion of MG63 cells transfected with pcDNA WWOX-AS1 was significantly suppressed compared with the pcDNA control group. \*P\<0.05 vs. the pcDNA control group. WWOX, WW domain-containing oxidoreductase; WWOX-AS1, WWOX antisense RNA 1; pcDNA, plasmid complementary DNA.
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###### 

Proliferation, migration and invasion of SAOS2 cells are enhanced following transfection with WWOX-AS1-si (magnification, ×200). (A) Proliferation of SAOS2 cells transfected with WWOX-AS1-si was significantly increased compared with the NC group. (B) Scratch wound-healing assays revealed that migration of SAOS2 cells transfected with WWOX-AS1-si was significantly enhanced compared with the NC group. (C) Matrigel invasion assays revealed that invasion of SAOS2 cells transfected with WWOX-AS1-si was significantly enhanced compared with the NC-si group. \*P\<0.05 vs. the NC-si group. WWOX, WW domain-containing oxidoreductase; WWOX-AS1, WWOX antisense RNA 1; NC, negative control; si, small interfering RNA.
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###### 

Characteristics of patients with osteosarcoma participating in the present study.

  Number   Age (years)   Sex   Stage   Tumor location
  -------- ------------- ----- ------- -------------------------
  1        16            M     III A   Proximal end of tibia
  2        27            F     III A   Proximal end of tibia
  3        41            F     III B   Proximal end of humerus
  4        40            F     I B     Proximal end of humerus
  5        40            F     II A    Distal end of humerus
  6        15            F     II B    Proximal end of tibia
  7        19            M     II A    Proximal end of tibia
  8        42            F     II B    Proximal end of tibia
  9        11            M     II A    Proximal end of tibia
  10       46            F     I A     Proximal end of femur
  11       29            M     II      Distal end of humerus
  12       15            M     II A    Proximal end of tibia
  13       15            M     II A    Proximal end of tibia
  14       10            M     I A     Distal end of femur
  15       12            F     II B    Proximal end of tibia
  16       44            M     II B    Proximal end of ulna
  17       40            F     II A    Distal end of femur
  18       41            M     I A     Proximal end of tibia
  19       43            F     I B     Distal end of femur
  20       19            F     II B    Proximal end of femur
  21       32            M     I A     Distal end of femur
  22       40            F     II B    Distal end of femur
  23       14            M     II B    Proximal end of humerus
  24       41            M     III A   Proximal end of humerus
  25       17            M     III A   Distal end of tibia
  26       12            M     II B    Proximal end of tibia
  27       42            F     I B     Proximal end of tibia
  28       14            F     I B     Distal end of femur
  29       21            F     I B     Distal end of femur
  30       20            M     II B    Proximal end of tibia
  31       19            F     II B    Proximal end of femur
  32       47            F     III A   Distal end of femur
  33       8             M     I B     Distal end of femur
  34       47            M     III A   Distal end of femur
  35       43            F     II B    Distal end of ulna
  36       15            M     III B   Distal end of tibia
  37       41            F     I A     Proximal end of humerus
  38       40            F     II A    Distal end of ulna
  39       41            F     I B     Distal end of ulna
  40       45            F     III B   Proximal end of tibia
  41       55            M     I A     Proximal end of tibia
  42       50            F     I B     Distal end of tibia
  43       12            M     III A   Distal end of femur
  44       18            F     III A   Proximal end of tibia
  45       15            M     II A    Proximal end of tibia
  46       16            F     I B     Distal end of femur
  47       43            F     II B    Distal end of tibia
  48       28            M     II B    Distal end of tibia
  49       40            F     III A   Proximal end of femur
  50       10            M     I B     Proximal end of tibia
  51       48            M     II A    Proximal end of femur
  52       42            F     I B     Proximal end of femur
  53       18            M     II A    Distal end of femur
  54       20            M     I A     Proximal end of femur
  55       45            F     I B     Proximal end of tibia
  56       45            F     II A    Distal end of femur
  57       43            F     III A   Distal end of femur
  58       15            M     I A     Proximal end of tibia
  59       18            M     III A   Distal end of femur
  60       42            M     III A   Distal end of femur
  61       43            M     I B     Distal end of femur
  62       16            M     III A   Distal end of tibia
  63       50            M     I B     Distal end of femur
  64       42            F     III A   Proximal end of tibia
  65       15            M     I B     Proximal end of humerus
  66       15            F     I B     Distal end of femur
  67       16            F     I A     Distal end of femur
  68       18            M     I B     Distal end of femur
  69       49            M     II A    Proximal end of tibia
  70       11            M     II A    Distal end of femur

Staging is based on Enneking system staging ([@b26-mmr-18-01-0779]). F, female; M, male.

###### 

Primers for quantitative polymerase chain reaction analysis.

             Primer sequence          
  ---------- ------------------------ ------------------------
  β-actin    CCACTGGCATCGTGATGGA      CGCTCGGTGAGGATCTTCAT
  *WWOX*     CAAGGGCGAGTGAAGCAGT      GGCGGAGGGTGGTATTTTGT
  WWOX-AS1   CAGAGTGAGAACCACTGGTGAT   CGAAGGATGAGTTAAAAAGTTT

WWOX, WW domain-containing oxidoreductase; WWOX-AS1, WW domain-containing oxidoreductase-antisense RNA 1.

###### 

Sequences for small interfering RNA analysis.

                       Sequence                    
  -------------------- --------------------------- -----------------------------
  WWOX-AS1-si-1        AUGGAUAUUUCCAAGCUGGAACCGA   UCGGUUCCAGCUUGGAAAUAUCCAUGU
  WWOX-AS1-si-2 (NC)   AUUGAAAAUGUAAGAACUAUUCUGA   UCAGAAUAGUUCUUACAUUUUCAAUCA

Si, small interfering; WWOX-AS1, WW domain-containing oxidoreductase-antisense RNA 1; NC, negative control.

###### 

Correlation between WW domain-containing oxidoreductase-antisense RNA 1 expression and clinicopathological characteristics of patients with osteosarcoma.

  Characteristics        Low WWOX-AS1 expression   High WWOX-AS1 expression   χ^2^     P-value
  ---------------------- ------------------------- -------------------------- -------- ---------
  Sex                                                                         0.9150   0.2430
    Male                 20                        16                                  
    Female               15                        19                                  
  Age (years)                                                                 2.8091   0.0937
    \<40                 22                        15                                  
    ≥40                  13                        20                                  
  Tumor size (cm)                                                             0.9790   0.4212
    \<6                  20                        24                                  
    ≥6                   15                        11                                  
  Differentiation                                                             1.5555   0.3096
    Well                   8                         9                                 
    Moderate             17                        11                                  
    Poor                 10                        15                                  
  Pulmonary metastasis                                                        5.1851   0.0228
    Yes                  12                          4                                 
    No                   23                        31                                  
  WHO grade                                                                   1.942    0.0121
    I                      7                       19                                  
    II                   17                        10                                  
    III                  11                          6                                 

WWOX-AS1, WW domain-containing oxidoreductase-antisense RNA 1; WHO, World Health Organization.

[^1]: Contributed equally
